☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
RET Fusion-Positive Thyroid Cancers
Roche's Gavreto (pralsetinib) Receives the US FDA's Approval for Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid...
December 2, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.